MINNEAPOLIS--(BUSINESS WIRE)--Marking a major step toward expanding minimally invasive endovascular therapies, Medtronic, Inc. (NYSE:MDT), today announced the start of the first human study of its Endurant Stent Graft System, an investigational treatment for abdominal aortic aneurysm (AAA).
